



Journal of the British Thoracic Society

Impact Factor: 6.226

Editor-in-Chief

J A Wedzicha (UK)

Editor

S L Johnston (UK)

Associate Editors

J S Brown (UK) J R Hurst (UK)
P M A Calverley (UK) D A Lomas (UK)
M Dusmet (UK) D M Mannino (USA)
J S Elborn (N Ireland) F D Martinez (USA)
A J Fisher (UK) C Robertson (Australia)
J M FitzGerald (Canada) B Schonhofer (Germany)
J A Fleetham (Canada) G A Silvestri (USA)
N M Foley (UK) G I Town (New Zealand)
I Hall (UK) M K B Whyte (UK)
R Hubbard (UK)

Statistical Editors

R Newson (UK)
T M McKeever (UK)
L Tata (UK)

Images Editors

J M FitzGerald (Canada)
J R Mayo (Canada)
J C Hogg (Canada)

Letters Editor

J R Hurst (UK)

Lung Alert Editors

A Bhowmik (UK)
J Quint (UK)

President, British Thoracic Society

P Ormerod

Editorial Office

BMJ Publishing Group Ltd, BMA House,
Tavistock Square, London WC1H 9JR, UK
T: +44 (0)20 7383 6147
F: +44 (0)20 7383 6668
E: thorax@bmjgroup.com
ISSN: 0040-6376 (print)
ISSN: 1468-3296 (online)

Disclaimer: *Thorax* is owned and published by the British Thoracic Society and BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association. The owners grant editorial freedom to the Editor of *Thorax*.

Thorax follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

Thorax is intended for medical professionals and is provided without warranty, express or implied. Statements in the Journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group Ltd, the British Thoracic Society or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage resulting from the use of *Thorax* or any information in it whether based on contract, tort or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2009 BMJ Publishing Group Ltd and the British Thoracic Society. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission of *Thorax*.

Thorax is published by BMJ Publishing Group Ltd, typeset by The Charlesworth Group and printed in the UK on acid-free paper by Latimer Trend & Co Ltd, Plymouth.

Thorax (USPS No: 002-143) is published monthly by BMJ Publishing Group and distributed in the USA by Pitney Bowes International Mailing Services Inc as mailing agent. Periodicals postage paid at Kearny, NJ, USA and additional mailing offices. POSTMASTER: send address changes to *Thorax*, PB International Mailing Services Inc, 500 US Hwy 46, Clifton, NJ 07011, USA.

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

iii1 Synopsis of recommendations

iii6 Section 1 Introduction

- 1.1 Scope of these guidelines
- 1.2 Introduction
- 1.3 Definitions
- 1.4 What is the target end user audience?
- 1.5 What patient populations are we including and excluding?
- 1.6 What changes have happened in the area of CAP since the 2004 guidelines?
- 1.7 Guidelines Committee membership
- 1.8 How the evidence was assimilated into the guidelines
- 1.9 Grading of recommendations
- 1.10 Plans for updating these guidelines
- 1.11 Implementation of the guidelines
- 1.12 Auditing CAP management

iii10 Section 2 Incidence, mortality and economic consequences

- 2.1 How common is adult CAP in the community and in hospital?
- 2.2 What is the mortality of CAP?
- 2.3 What are the economic consequences of CAP?
- 2.4 What comments can be made about cost effectiveness of different therapies?

iii12 Section 3 Aetiology and epidemiology

- 3.1 Introduction
- 3.2 What are the causes of adult CAP in the UK?
- 3.3 What are the causes of adult CAP in similar populations elsewhere in the world?
- 3.4 How does the aetiology differ in certain geographical areas
- 3.5 Is the aetiology different in specific population groups?
- 3.6 What are the epidemiological patterns of pathogens causing CAP and is this information useful to the clinician?

iii15 Section 4 Clinical features

- 4.1 Can the aetiology of CAP be predicted from clinical features?
- 4.2 Specific clinical features of particular respiratory pathogens
- 4.3 CAP in elderly patients: are risk factors and clinical features different?
- 4.4 Aspiration pneumonia

iii17 Section 5 Radiological, general and microbiological investigations

- 5.1 When should a chest radiograph be performed in the community for patients presenting with suspected CAP?
- 5.2 When should a chest radiograph be performed in hospital for patients presenting with suspected CAP?
- 5.3 Are there characteristic features that enable the clinician to predict the likely pathogen from the chest radiograph?
- 5.4 What is the role of CT lung scans in CAP?
- 5.5 How quickly do chest radiographs improve after CAP?
- 5.6 When should the chest radiograph be repeated during recovery and what action should be taken if the radiograph has not returned to normal?
- 5.7 What general investigations should be done in a patient with suspected CAP in the community?
- 5.8 What general investigations should be done in patients admitted to hospital?
- 5.9 Why are microbiological investigations performed in patients with CAP?
- 5.10 What microbiological investigations should be performed in patients with suspected CAP in the community?
- 5.11 What microbiological investigations should be performed in patients admitted to hospital with CAP?

iii25 Section 6 Severity assessment

- 6.1 Why is severity assessment important?
- 6.2 What clinical factors and investigations are associated with a poor prognosis on univariate and multivariate analysis?

- 6.3 What predictive models for assessing severity on or shortly after hospital admission have been tested?
- 6.4 What severity assessment strategy is recommended for CAP?
- 6.5 Severity assessment of CAP in patients seen in the community
- 6.6 Severity assessment of CAP in patients seen in hospital
- 6.7 Reviewing severity status after initial assessment in hospital

iii28 Section 7 General management in the community and in hospital

- 7.1 What general management strategy should be offered to patients treated in the community?
- 7.2 What review policy should be adopted in patients managed in the community?
- 7.3 What general management strategy should be offered to patients in hospital?
- 7.4 What advice should be given regarding critical care management of CAP?
- 7.5 What arrangements should be made for follow-up after hospital discharge and by whom?

iii32 Section 8 Antibiotic management

- 8.1 Introduction
- 8.2 Antibiotic stewardship and the individual clinician's responsibility to prevent the overuse of antibiotics when managing CAP
- 8.3 Antibiotic resistance of respiratory pathogens
- 8.4 Newer antibiotics
- 8.5 Clinical studies of management and international differences in recommendations
- 8.6 Formulations of these recommendations
- 8.7 Empirical antibiotic choice for CAP treated in the community
- 8.8 Should general practitioners administer antibiotics prior to hospital transfer in those patients who need admission?
- 8.9 When should the first dose of antibiotics be given to patients admitted to hospital with CAP?
- 8.10 Empirical antibiotic choice for adults hospitalised with low severity CAP
- 8.11 Empirical antibiotic choice for adults hospitalised with moderate severity CAP
- 8.12 Empirical antibiotic choice for adults hospitalised with high severity CAP
- 8.13 When should the intravenous or the oral route be chosen?

- 8.14 When should the intravenous route be changed to oral?
- 8.15 Which oral antibiotics are recommended on completion of intravenous therapy?
- 8.16 How long should antibiotics be given for?
- 8.17 Failure of initial empirical therapy
- 8.18 Antibiotic stewardship and avoiding inappropriate antibiotic prescribing for CAP
- 8.19 What are the optimum antibiotic choices when specific pathogens have been identified?
- 8.20 Specific issues regarding the management of Legionnaires' disease
- 8.21 Specific issues regarding Pantone-Valentine Leukocidin-producing *Staphylococcus aureus*

iii43 Section 9 Complications and failure to improve

- 9.1 What factors and action should be considered in patients who fail to improve in hospital?
- 9.2 What are the common complications of CAP?

iii44 Section 10 Prevention and vaccination

- 10.1 Influenza and pneumococcal vaccination
- 10.2 Smoking cessation

iii44 Section 11 Committee membership and acknowledgements

- 11.1 Membership of the BTS Community Acquired Pneumonia Guidelines Committee and affiliations
- 11.2 Authorship of sections of the guidelines
- 11.3 Acknowledgements
- 11.4 Declarations of interest

iii45 References

iii54 Appendix 1 Checklist used by reviewers for appraising studies

iii54 Appendix 2 Additional checklist used for appraising studies to inform pneumonia aetiology

iii55 Appendix 3 Types of study and levels of evidence used to illuminate specific clinical questions

iii55 Appendix 4 Generic levels of evidence and guideline statement grades, appropriate across all types of clinical questions